HBV-related HCC, clinical issues and therapy

Digestive and Liver Disease

Volumn 43, Issue SUPPL. 1, 2011, Pages

  Iavarone, Massimo ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cirrhosis; Hepatitis B virus; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; ANTIVIRUS AGENT; IODINATED POPPYSEED OIL; PLACEBO; SORAFENIB; VIRUS DNA; YTTRIUM 90;

ADVANCED CANCER; ANTIVIRAL THERAPY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE SEVERITY; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT INDICATION; TUMOR BIOPSY; VIRUS CARRIER;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION;

EID: 78650638975     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60690-1     Document Type: Article

References (76)

1. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Vol VIII, IARC Scientific Publications No. 155 2002, IARC, Lyon, France.
2. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538.
3. Raimondo G, Pollicino T, Squadrito G What is the clinical impact of occult hepatitis B virus infection. Lancet 2005, 365:638-640.
4. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010, 51(5):1531-1537.
5. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155:323-331.
6. Ming L, Thorgeirsson S, Gail MH, et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002, 36:1214-1220.
7. Di Bisceglie AM Hepatitis B and hepatocellular carcinoma. Hepatology 2009, 49:S56-S60.
8. Chen CJ, Yang HI, Su J, REVEAL-HBV Study Group, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295(1):65-73.
9. Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010, 53(2):348-356.
10. Bruix J, Sherman M, Llovet JM, for the EASL Panel of Experts on HCC, et al. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona - 2000 EASL Conference. J Hepatol 2001, 35:421-430.
11. El-Serag HB, Rudolph R Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
12. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001, 120:1763-1773.
13. Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
14. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
15. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69(18):7385-7392.
16. Shiratori Y, Shina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995, 22:1027-1033.
17. Miyagawa S, Kawasaki S, Makuuchi M Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: Tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology 1996, 24:307-310.
18. Stroffolini T, Andreone P, Andriulli A, et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998, 29:944-952.
19. Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008, 28:1067-1077.
20. Sherman M, Peltekian KM, Lee C Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995, 22:432-438.
21. Trevisani F, Magini G, Santi V, for the Italian Liver Cancer (ITA.LI.CA) Group, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol 2007, 102:1022-1031.
22. Toyoda H, Kumada T, Kiriyama S, et al. Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. Clin Gastroenterol Hepatol 2006, 4:1170-1176.
23. Chalasani N, Said A, Ness R, et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 1999, 94:2224-2229.
24. El-Serag HB, Mason AC Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
25. Bruix J, Sherman M Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
26. Arguedas MR, Chen VK, Eloubeidi MA, et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003, 98:679-690.
27. Lin OS, Keeffe EB, Sanders GD, et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004, 19:1159-1172.
28. Trinchet JC, Beaugrand M. A randomized trial comparing 3-month vs. 6-month screening for HCC by ultrasonography in cirrhosis. Proceedings of the ILCA First Annual Conference 2007, Barcelona, 5-7 October 2007, 11.
29. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325:675-680.
30. Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19:61-66.
31. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001, 48:251-259.
32. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000, 32:842-846.
33. Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997, 123:357-360.
34. Zhang BH, Yang BH, Tang ZY Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:417-422.
35. Marrero JA, Hussain HK, Nghiem HV, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplant 2005, 11:281-289.
36. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47:97-104.
37. Vilana R, Forner A, Bianchi L, et al. Intrahepatic peripheral cholangio-carcinoma in cirrhotic patients may display a vascular pattern similar to hepatocellular carcinoma on contrast enhanced ultrasound (pNA). Hepatology 2010, 51(6):2020-2029.
38. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009, 30(1):37-47.
39. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126:1005-1014.
40. Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010, 30(1):61-74.
41. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996, 111(4):1018-1022.
42. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200-207.
43. Lee WC, Jeng LB, Chen MF Estimation of prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg 2002, 89:311-316.
44. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
45. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998, 27:1572-1577.
46. Bismuth H, Majno PE, Adam R Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999, 19:311-322.
47. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33:1080-1086.
48. Parfitt JR, Marotta P, Al Ghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transplant 2007, 13:543-551.
49. Lesurtel M, Mullhaupt B, Pestalozzi BC, et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006, 6:2644-2650.
50. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transplant 2007, 13:272-279.
51. Sala M, Llovet JM, Villana R, for the Barcelona Clinic Liver Cancer (BCLC) Group, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004, 40:1352-1360.
52. Arii S, Yamaoka Y, Futagawa S, for the Liver Cancer Study Group of Japan, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000, 32:1224-1229.
53. Brunello F, Veltri A, Carucci P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008, 43(6):727-735.
54. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003, 228:235-240.
55. Lin OS, Keeffe EB, Sanders GD, et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004, 19:1159-1172.
56. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005, 54:1151-1156.
57. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129:122-130.
58. Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010, 52(3):380-388.
59. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 2008, 47:82-89.
60. Lampertico P, Viganò M, Bhoori S, et al. Excellent 5-year overall survival in patients with HBV-related cirrhosis undergoing liver transplantation for hepatocellular carcinoma. Hepatology 2008, 48(Suppl 1):584A.
61. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006, 43(2):233-240.
62. Llovet JM, Bruix J Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429-442.
63. Lin DY, Liaw YF, Lee TY, et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial. Gastroenterology 1988, 94:453-456.
64. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995, 332:1256-1261.
65. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution. Hepatology 1998, 27:1578-1583.
66. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepato-cellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998, 28:129-134.
67. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
68. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359(9319):1734-1739.
69. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46:474-481.
70. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997, 26:1156-1161.
71. 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008, 47:71-81.
72. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293-4300.
73. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34.
74. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. Cancer 2009, 115(3):616-623.
75. Ringe B, Pichlmayr R, Wittekind C, et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991, 15:270-285.
76. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991, 214:221-229.